17,751,500 Shares of Common Stock ($0.001 Par Value) Series 1 Warrants to Purchase up to 13,313,625 Shares of Common Stock Series 2 Warrants to Purchase up to 7,988,175 Shares of Common Stock SCYNEXIS, Inc. Common Stock EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • March 7th, 2018 • Scynexis Inc • Pharmaceutical preparations • New York
SCYNEXIS, Inc., a Delaware corporation (the “Issuer”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom Guggenheim Securities, LLC is acting as representative (“you” or the “Representative”) an aggregate of (i) 17,751,500 shares of the Issuer’s Common Stock, $0.001 par value (the “Shares”), (ii) Series 1 warrants, each of which can be exercised to purchase 0.75 of a share of Common Stock and, in the aggregate, to purchase up to 13,313,625 shares of Common Stock (the “Series 1 Warrants”) and (iii) Series 2 warrants, each of which can be exercised to purchase 0.45 of a share of Common Stock and, in the aggregate to purchase up to 7,988,175 shares of Common Stock (the “Series 2 Warrants” and , together with the Series 1 Warrants, the “Warrants” and, together with the Shares, the “Securities”) in the form attached hereto as Exhibit A. The respective amounts of the Securities to be so purchased by the several Underwriters are set forth op
